NASDAQ:MCRB - Seres Therapeutics Stock Price, Forecast & News

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Seres Therapeutics Inc (NASDAQ:MCRB) released its earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.26) by $0.03. The biotechnology company had revenue of $7.03 million for the quarter, compared to analyst estimates of $6.69 million. View Seres Therapeutics' Earnings History.

Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Seres Therapeutics.

6 brokers have issued 1 year price objectives for Seres Therapeutics' stock. Their forecasts range from $4.00 to $15.00. On average, they expect Seres Therapeutics' share price to reach $9.00 in the next year. This suggests a possible upside of 156.4% from the stock's current price. View Analyst Price Targets for Seres Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seres Therapeutics.

News stories about MCRB stock have trended somewhat positive on Monday, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Seres Therapeutics earned a news impact score of 1.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Seres Therapeutics.

Seres Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,600,000 shares, an increase of 15.9% from the January 15th total of 3,970,000 shares. Based on an average trading volume of 211,200 shares, the days-to-cover ratio is presently 21.8 days. Currently, 11.2% of the shares of the stock are short sold. View Seres Therapeutics' Current Options Chain.

Some companies that are related to Seres Therapeutics include Karyopharm Therapeutics (KPTI), Gossamer Bio (GOSS), Kiniksa Pharmaceuticals (KNSA), Achillion Pharmaceuticals (ACHN), I-Mab (ARQT), Radius Health (RDUS), Amphastar Pharmaceuticals (AMPH), Stoke Therapeutics (STOK), Cytokinetics (CYTK), Homology Medicines (FIXX), Phathom Pharmaceuticals (PHAT), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals (ANIP), Rhythm Pharmaceuticals (RYTM) and Collegium Pharmaceutical (COLL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include Opko Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), Walt Disney (DIS), Novavax (NVAX), Verastem (VSTM), Alibaba Group (BABA), Anavex Life Sciences (AVXL), Exelixis (EXEL) and NVIDIA (NVDA).

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Seres Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (11.82%), Nikko Asset Management Americas Inc. (11.82%), ARK Investment Management LLC (10.39%), FMR LLC (9.28%), Renaissance Technologies LLC (1.59%) and State Street Corp (1.00%). Company insiders that own Seres Therapeutics stock include Eric D Shaff, John G Aunins, Marcus Chapman, Noubar Afeyan, Roger Pomerantz and Thomas Desrosier. View Institutional Ownership Trends for Seres Therapeutics.

MCRB stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, AQR Capital Management LLC, Jane Street Group LLC, Bank of America Corp DE and ProShare Advisors LLC. View Insider Buying and Selling for Seres Therapeutics.

MCRB stock was acquired by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., ARK Investment Management LLC, Mayo Clinic, Jacobs Levy Equity Management Inc., State Street Corp, Oxford Asset Management LLP and Russell Investments Group Ltd.. View Insider Buying and Selling for Seres Therapeutics.

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MCRB stock can currently be purchased for approximately $3.51.

Seres Therapeutics has a market capitalization of $245.74 million and generates $28.27 million in revenue each year. The biotechnology company earns $-98,940,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe.View Additional Information About Seres Therapeutics.

The official website for Seres Therapeutics is http://www.serestherapeutics.com/.

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]